Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC

Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.